Enspire DBS Therapy

Executive Summary

Enspire DBS Therapy, Inc. is a clinical-stage medical device company pioneering a novel deep brain stimulation (DBS) system for post-stroke motor recovery. The company's technology combines an implantable DBS device with targeted rehabilitation therapy to re-establish neurological input and promote plasticity in the brain, specifically addressing chronic, moderate-to-severe arm impairment following ischemic stroke. Founded in 2016 and headquartered in Austin, Texas, Enspire operates in the neuroscience and medical device sectors, targeting a significant unmet need: over 7 million stroke survivors in the U.S. alone, many with persistent motor deficits. While the company remains private with limited disclosed funding, its preclinical and early clinical data have shown promise in restoring motor function. Enspire's approach is differentiated by its focus on neuroplasticity and a closed-loop stimulation paradigm, which could set a new standard of care in stroke rehabilitation. The company's progress depends on successful clinical validation and regulatory navigation, but its niche focus and innovative platform position it as a potential leader in neuromodulation for stroke recovery.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Pivotal Clinical Trial for Post-Stroke DBS System75% success
• Q4 2026FDA Breakthrough Device Designation or Investigational Device Exemption (IDE) Approval80% success
• Q2 2027Publication of Phase I/II Clinical Data in Peer-Reviewed Journal70% success